Assessment of No Evidence of Disease Activity (NEDA-3) in alemtuzumab-treated patients with aggressive multiple sclerosis who failed multiple disease-modifying drugs

被引：0

作者：

Prosperini, L. ^{[1
]}

Annovazzi, P. ^{[2
]}

Boffa, L. ^{[3
]}

Buscarinu, C. ^{[4
]}

Gallo, A. ^{[5
]}

Matta, M. ^{[6
]}

Moiola, L. ^{[7
]}

Musu, L. ^{[8
]}

Perini, P. ^{[9
]}

Avolio, C. ^{[10
]}

Rottoli, M. R. ^{[11
]}

Bianco, A. ^{[12
]}

Farina, D. ^{[13
]}

Ferraro, E. ^{[14
]}

Francia, A. ^{[1
]}

Granella, F. ^{[15
]}

Grimaldi, L. ^{[16
]}

Laroni, A. ^{[17
]}

Lus, G. ^{[5
]}

Patti, F. ^{[18
]}

Pucci, E. ^{[19
]}

Repice, A. M. ^{[20
]}

Sarchielli, P. ^{[21
]}

机构：

[1] Univ Roma La Sapienza, Neurol & Psychiat, Rome, Italy

[2] S Antonio Abate Hosp, Gallarate, Italy

[3] Univ Roma Tor Vergata, Rome, Italy

[4] S Andrea Hosp, Ctr Expt Neurol Therapies CENTERS, Rome, Italy

[5] Univ Naples 2, Dept Med Surg Neurol Metab & Aging Sci, Naples, Italy

[6] S Luigi Gonzaga Hosp, Reg MS Ctr, Orbassano, Italy

[7] Univ Vita Salute San Raffaele, S Raffaele Sci Inst, Milan, Italy

[8] ASL 8 Cagliari Univ, Cagliari, Italy

[9] Univ Hosp, MS Ctr, Dept Neurosci, Padua, Italy

[10] Univ Hosp, Dept Med & Surg Sci, Foggia, Italy

[11] Papa Giovanni XXIII Hosp, Bergamo, Italy

[12] Sch Med A Gemelli, Inst Neurol, Rome, Italy

[13] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy

[14] S Filippo Neri Hosp, Rome, Italy

[15] Univ Parma, Dept Neurosci, Parma, Italy

[16] Fdn Ist San Raffaele G Giglio, Cefalu, Italy

[17] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy

[18] Univ Catania, Neurosci Sect, Dept Med & Surg Sci & Adv Technol, Catania, Italy

[19] ASUR Marche AV3, Neurol Unit, Macerata, Italy

[20] Careggi Hosp, Neurol Unit, Florence, Italy

[21] Univ Perugia, Neurol Unit, Perugia, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P614

引用

页码：284 / 285

页数：2

共 50 条

[1] Two-year assessment of No Evidence of Disease Activity (NEDA-3) and disability regression in patients with aggressive multiple sclerosis treated with alemtuzumab
Prosperini, L.
Annovazzi, P.
Ruggieri, S.
Boffa, L.
Buscarinu, M. C.
Gallo, A.
Matta, M.
Moiola, L.
Musu, L.
Perini, P.
Avolio, C.
Barcella, V.
Bianco, A.
Farina, D.
Ferraro, E.
Francia, A.
Granella, F.
Grimaldi, L. M. E.
Laroni, A.
Lus, G.
Patti, F.
Pucci, E.
Repice, A. M.
Sarchielli, P.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 480 - 481
[2] Achieving No Evidence of Disease Activity-3 (NEDA-3) in cladribine and monoclonal antibodies treated multiple sclerosis patients
Alonso, R.
Lazaro, L.
Casas, M.
Pita, C.
Cohen, L.
Liguori, N. Fernandez
Rojas, J. I.
Pappolla, A.
Patrucco, L.
Cristiano, E.
Serena, M. Alonso
Marcos, B.
Vrech, C.
Piedrabuena, R.
Lopez, P.
Deri, N.
Luetic, G.
Miguez, J.
Cabrera, M.
Martinez, A.
Zanga, G.
Tkachuk, V.
Tizio, S.
Contentti, E. Carnero
Knorre, E.
Leguizamon, F.
Mainella, C.
Nofal, P.
Liwacki, S.
Hryb, J.
Chiganer, E.
Menichini, M. L.
Pestchanker, C.
Garcea, O.
Silva, B.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 382 - 383
[3] No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab
Margoni, Monica
Rinaldi, Francesca
Riccardi, Alice
Franciotta, Silvia
Perini, Paola
Gallo, Paolo
JOURNAL OF NEUROLOGY, 2020, 267 (01) : 100 - 105
[4] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
Trojano, Maria
Paolicelli, Damiano
Fuiani, Aurora
Pellegrini, Fabio
Iaffaldano, Pietro
Direnzo, Vita
D'Onghia, Mariangela
NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S225 - S226
[5] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
Maria Trojano
Damiano Paolicelli
Aurora Fuiani
Fabio Pellegrini
Pietro Iaffaldano
Vita Direnzo
Mariangela D’Onghia
Neurological Sciences, 2008, 29 : 225 - 226
[6] Serum Neurofilament (sNFL) dosage in the management of patients with multiple sclerosis and no evidence of disease activity (NEDA-3)
Malucchi, Simona
Martire, Serena
Bava, Cecilia
Valentino, Paola
Lo Re, Marianna
Bertolotto, Antonio
Di Sapio, Alessia
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 958 - 958
[7] Predictors of relapses in patients with multiple sclerosis treated with disease-modifying drugs
Steinman, L.
Obi-Tabot, E.
Wang, H.
Guilhaume, C.
Sondhi, M.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S413 - S413
[8] No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab
Monica Margoni
Francesca Rinaldi
Alice Riccardi
Silvia Franciotta
Paola Perini
Paolo Gallo
Journal of Neurology, 2020, 267 : 100 - 105
[9] Use of Disease-Modifying Drugs in Multiple Sclerosis
Wurzius, F. Q.
Silva, C. B.
de Vecino, M. A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 102 - 103
[10] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
Meletiche, D. M.
Kozma, C.
Dickson, M.
VALUE IN HEALTH, 2009, 12 (03) : A193 - A193

← 1 2 3 4 5 →